Moderna shares surged approximately 177% on Wednesday after the company and Merck announced positive Phase 3 melanoma vaccine data [1].
The results mark a significant milestone in the development of personalized cancer treatments, signaling a potential shift in how late-stage skin cancer is managed.
Moderna (NASDAQ:MRNA) reported the positive late-stage trial results on Aug. 19, 2026 [3]. Following the announcement, the company said it plans to submit the data to the U.S. Food and Drug Administration for review [1]. The stock closed at $174.38 after the rally [2].
The price movement created a massive squeeze for investors betting against the company. Short sellers incurred losses totaling $5.5 billion [4].
While some market observers linked the broader U.S. equity rally to Moderna's performance, other reports suggested the market rose because the U.S. Treasury Department increased buybacks of long-dated government debt [5]. This policy shift led to a sharp pullback in yields, providing a tailwind for various stocks across the NASDAQ [5].
Moderna has utilized mRNA technology, originally scaled for COVID-19 vaccines, to target specific markers in melanoma patients. The partnership with Merck has focused on combining this vaccine approach with existing immunotherapy to improve patient outcomes [1].
The company's rapid valuation increase reflects investor confidence in the scalability of mRNA platforms beyond infectious diseases. If the FDA approves the treatment, it would represent one of the first successful applications of a personalized mRNA vaccine for oncology [1].
“Moderna shares surged approximately 177% on Wednesday”
The success of the Phase 3 trial validates mRNA technology as a viable tool for oncology, potentially opening the door for vaccines targeting other types of cancer. The massive financial loss for short sellers underscores the high-risk, high-reward nature of biotech investing, where a single clinical trial result can fundamentally rewrite a company's market valuation overnight.
